Chan, Steven
MEDICAL BIOPHYSICS
University of Toronto
Canada
Biography
Dr. Chan completed his undergraduate training (Immunology specialist program) at University of Toronto in 2000. He received his medical and research training at Stanford University in California where he earned his MD (2008) and PhD (2006) degree in Immunology. He subsequently completed his internal medicine residency (2010) and adult hematology fellowship (2014) at Stanford Hospital and Clinics. He conducted his postdoctoral research under the supervision of Dr. Ravindra Majeti at the Stanford Cancer Institute where he studied the isocitrate dehydrogenase mutation in acute myeloid leukemia and its effects on mitochondrial function. He joined Princess Margaret Cancer Centre as a Clinician Scientist in 2015. Dr. Chan completed his undergraduate training (Immunology specialist program) at University of Toronto in 2000. He received his medical and research training at Stanford University in California where he earned his MD (2008) and PhD (2006) degree in Immunology. He subsequently completed his internal medicine residency (2010) and adult hematology fellowship (2014) at Stanford Hospital and Clinics. He conducted his postdoctoral research under the supervision of Dr. Ravindra Majeti at the Stanford Cancer Institute where he studied the isocitrate dehydrogenase mutation in acute myeloid leukemia and its effects on mitochondrial function. He joined Princess Margaret Cancer Centre as a Clinician Scientist in 2015.
Research Interest
The goals of our research program are: 1) to determine the role of mitochondria in the development and maintenance of leukemic stem cells in acute myeloid leukemia (AML), and 2) to discover novel therapeutic strategies that target AML stem cells using functional genomic screens. To achieve these goals, our laboratory employs a range of genetic and analytical tools including CRISPR/Cas9 technology and genetically-encoded fluorescent biosensors in human-derived AML samples. We employ CRISPR/Cas9-based genetic screens to identify unique vulnerabilities associated with specific mutations in AML (synthetic lethal screens). In addition, these screens are used to identify therapeutic strategies against drug resistance mechanisms.
